Published July 2019
| Version v1
Journal article
Should Oncologists Recommend Cannabis?
Creators
- 1. University of California San Francisco, Hematology-Oncology, Zuckerberg San Francisco General, Integrative Oncology, UCSF Osher Center for Integrative Medicine, Professor of Clinical Medicine (United States)
Description
Opinion Statement
Cannabis is a useful botanical with a wide range of therapeutic potential. Global prohibition over the past century has impeded the ability to study the plant as medicine. However, delta-9-tetrahydrocannabinol (THC) has been developed as a stand-alone pharmaceutical initially approved for the treatment of chemotherapy-related nausea and vomiting in 1986. The indication was expanded in 1992 to include treatment of anorexia in patients with the AIDS wasting syndrome. Hence, if the dominant cannabinoid is available as a schedule III prescription medication, it would seem logical that the parent botanical would likely have similar therapeutic benefits. The system of cannabinoid receptors and endogenous cannabinoids (endocannabinoids) has likely developed to help us modulate our response to noxious stimuli. Phytocannabinoids also complex with these receptors, and the analgesic effects of cannabis are perhaps the best supported by clinical evidence. Cannabis and its constituents have also been reported to be useful in assisting with sleep, mood, and anxiety. Despite significant in vitro and animal model evidence supporting the anti-cancer activity of individual cannabinoids—particularly THC and cannabidiol (CBD)—clinical evidence is absent. A single intervention that can assist with nausea, appetite, pain, mood, and sleep is certainly a valuable addition to the palliative care armamentarium. Although many healthcare providers advise against the inhalation of a botanical as a twenty-first century drug-delivery system, evidence for serious harmful effects of cannabis inhalation is scant and a variety of other methods of ingestion are currently available from dispensaries in locales where patients have access to medicinal cannabis. Oncologists and palliative care providers should recommend this botanical remedy to their patients to gain first-hand evidence of its therapeutic potential despite the paucity of results from randomized placebo-controlled clinical trials to appreciate that it is both safe and effective and really does not require a package insert.Additional details
Identifiers
Publishing Information
- Journal Title
- Current Treatment Options in Oncology (Online)
- Journal Volume
- 20
- Journal Issue
- 7
- Journal Page Range
- p. 1-12
- ISSN
- 1534-6277
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 55030809
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- AIDS; ANALGESICS; ANOREXIA; CHEMOTHERAPY; CLINICAL TRIALS; DRUG DELIVERY; IN VITRO; INGESTION; INHALATION; MEDICAL PERSONNEL; NARCOTICS; NAUSEA; NEOPLASMS; PAIN; PATIENTS; RECEPTORS; SLEEP; VOMITING
- Descriptors DEC
- CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DISEASES; DRUGS; IMMUNE SYSTEM DISEASES; INFECTIOUS DISEASES; INTAKE; MEDICINE; MEMBRANE PROTEINS; ORGANIC COMPOUNDS; PERSONNEL; PROTEINS; SYMPTOMS; TESTING; THERAPY; VIRAL DISEASES; ZOONOTIC DISEASES
Optional Information
- Copyright
- Copyright (c) 2019 Springer Science+Business Media, LLC, part of Springer Nature
- Notes
- http://www.springer-ny.com